xevinapant, Xevinapant Placebo
MS202359_0002
Phase 3 small_molecule active
Quick answer
xevinapant, Xevinapant Placebo for Resected squamous cell carcinoma of the head and neck is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Resected squamous cell carcinoma of the head and neck
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active